I have Type 1 diabetes. I love to write. I’m happy when I am helping others. I speak up when it’s important. I have a passion for sharing knowledge and learning new technology. I was BORN to BLOG!

I’ve met so many other T1Ds on this journey who are cool and love to help others. We put our heads and hearts together … to bring more resources and knowledge to our amazing diabetes community. We’re making improvements every day … come back often, let us know what you think. And my gratitude for my amazing webmaster, Dave (an honorary T1D)!

And thank you for stopping by!
— Joanne Laufer Milo, The Savvy Diabetic

Savvy Updates, 1/17/22:  Dexcom G7 Update with Kevin Sayer, “Medical” Wearables, NAFLD & T1D, Pancreatic Exocrine Insufficiency, Stair Walking & Insulin Sensitivity

Savvy Updates, 1/17/22: Dexcom G7 Update with Kevin Sayer, “Medical” Wearables, NAFLD & T1D, Pancreatic Exocrine Insufficiency, Stair Walking & Insulin Sensitivity

Fitbit and Apple know their smartwatches aren't medical devices. But do you? was written by Lisa Eadicicco for cnet.com, 14 January 2022.  The line is blurring as wearables become more advanced. And it's only getting more complicated. The Fitbit Sense and similar...

read more
Savvy Updates, 1/3/22: Beta Bionics Pivotal Trial, Log4j Cybersecurity, Exercise at High Altitudes, Cannabis and DKA, Amazon Pharmacy Shake-up, Endo Fellowships

Savvy Updates, 1/3/22: Beta Bionics Pivotal Trial, Log4j Cybersecurity, Exercise at High Altitudes, Cannabis and DKA, Amazon Pharmacy Shake-up, Endo Fellowships

Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial was released by Beta Bionics on GlobeNewswire.com, 22 December 2021.   Beta Bionics,...

read more
Savvy about T1D and Hangovers

Savvy about T1D and Hangovers

Happy Holidays to everyone! Aside from gatherings, lots of food, unusual consumption of carbs and sweets, less exercise and travel, alcohol consumption may or often does go up! The Savvy Diabetic wants to share this useful article all about too much drinking and...

read more
Savvy Update, 12/20/21: Stock Market on CGMs & Insulin Pumps, J&J Invokana Dangers, Medtronic FDA Warning Letter, Insulin Pumps and Body Fat, AI Algorithm/Alpha Fold

Savvy Update, 12/20/21: Stock Market on CGMs & Insulin Pumps, J&J Invokana Dangers, Medtronic FDA Warning Letter, Insulin Pumps and Body Fat, AI Algorithm/Alpha Fold

DIABETES BUSINESS NEWS:   Diabetes tech market still has a clear favorite was published by Jason Aycock for SeekingAlpha.com, 15 December 2021.   On the Continuous Glucose Monitoring, the market stayed strong this year, likely growing in the low-...

read more
Savvy Update, 12/13/21:  Tandem Getting Bigger, 1 in 10 Adults Have Diabetes Worldwide, Stem Cell Research, Cone Snail Venom, Kidney Disease, Diabetes & Complications, Embecta (BD)

Savvy Update, 12/13/21: Tandem Getting Bigger, 1 in 10 Adults Have Diabetes Worldwide, Stem Cell Research, Cone Snail Venom, Kidney Disease, Diabetes & Complications, Embecta (BD)

Tandem Diabetes Care targets 1M customers by 2027 we reported by Ricky Zipp for MedTechDive.come, 7 December 2021.   Tandem Diabetes Care projects that its worldwide customer base will triple to 1 million by 2027 as the insulin pump maker launches multiple...

read more
Savvy Updates 12/6/21: Omnipod 5 Delayed, Abbott vs. Dexcom Lawsuits, FDA Med Device Recalls UP, T1D Kids and Diabetes “Types”, Sleep Impacts Morning Glucose, Coronary Calcium Scan?, Drugs that Maintain Beta Cell Function, BG and Dental Health

Savvy Updates 12/6/21: Omnipod 5 Delayed, Abbott vs. Dexcom Lawsuits, FDA Med Device Recalls UP, T1D Kids and Diabetes “Types”, Sleep Impacts Morning Glucose, Coronary Calcium Scan?, Drugs that Maintain Beta Cell Function, BG and Dental Health

Insulet drops 10% as CEO indicates launch of Omnipod insulin product likely delayed was reported by Jonathan M. Block for SeekingAlpha.com, 3 December 2021.   Insulet CEO Shacey Petrovic said that the FDA will likely not complete its review of the company's...

read more
Share This
Skip to content